TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRN...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zhang, Qifang, Hossain, Dewan Md Sakib, Nechaev, Sergey, Kozlowska, Anna, Zhang, Wang, Liu, Yong, Kowolik, Claudia M., Swiderski, Piotr, Rossi, John J., Forman, Stephen, Pal, Sumanta, Bhatia, Ravi, Raubitschek, Andrew, Yu, Hua, Kortylewski, Marcin
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2013
Soggetti:
Gene Therapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578952/
https://ncbi.nlm.nih.gov/pubmed/23287859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-442590
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi